

National Immunisation Advisory Committee

MEETING DETAILS

Date (Venue)	11.07.2022 (Teams)
--------------	--------------------

MINUTES

Introductions	Committee members and others attending were welcomed.
Statement of Interests	No conflicts of interest declared.
Governance	Progress in transformation to National Immunisation Technical Advisory Group (NITAG) reviewed.
SARS-CoV-2 (COVID-19)	ECDC/EMA press release with updated recommendations on additional booster doses of COVID-19 vaccines (dated 11.07.2022) shared with Committee. Proposed recommendations presented and discussed. Will be revised and updated.
Bacillus Calmette-Guérin (BCG)	BCG recommendations were presented and discussed. Finalised recommendations will be circulated to the Committee for approval.
Influenza	HSE/NIO working to further promote influenza vaccination in children this autumn.
Human Papilloma Virus (HPV) Vaccine	HPV dose schedule was discussed and feedback from meeting with JCVI Chair shared. Recommendations proposed and accepted in principle by the Committee. Written documentation to be prepared for submission to DOH.
Varicella Zoster Virus	HIQA HTA on chickenpox vaccine ongoing. Zoster vaccine HTA to follow.
Primary Childhood Immunisation Schedule	Committee notified that supplies of combined Hib/MenC vaccine will expire in March 2026. A revised primary childhood immunisation schedule with Committee agreement before 1 January 2023 is required. Proposed options were presented to the Committee. Draft recommendations will be presented in September, with aim to finalise by December 2022.
Monkeypox	Expansion to monkeypox vaccination programme to high-risk groups discussed. Verbal request from DOH to consider recent ECDC statement regarding monkeypox vaccination. Recommendation update pending.
Chapter Updates	Chapter updates issued since 25 May 2022: Anaphylaxis (2 updates), Chapter 8 (Hepatitis A), Chapter 9a (Hepatitis B), Chapter 12 (Measles), Chapter 14 (Mumps), Chapter 20a Smallpox ((Variola)/Monkeypox; 3 updates).
Vaccine Injury Redress Scheme	Continued to advocate for introduction of scheme.